Artiva Biotherapeutics (ARTV) Return on Sales (2023 - 2024)
Artiva Biotherapeutics' (ARTV) quarterly Return on Sales came in at 3.94% in Q4 2024, down 389.0% year-on-year from 1.36% in Q1 2024, and down 1074.04% on a QoQ basis from 0.34% in Q3 2024.
Artiva Biotherapeutics (ARTV) Return on Sales (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 2 years of Return on Sales data on file, last reported at 3.94% in Q4 2024.
- On a quarterly basis, Return on Sales fell 389.0% year-over-year to 3.94% in Q4 2024; TTM through Dec 2024 was 3.94%, a N/A change from a year earlier, with the FY2024 full-year figure at 2.46%, down 246.0% from the prior year.
- Return on Sales for Q4 2024 stood at 3.94%, down from 0.34% in the prior quarter.
- Over the last five years, Return on Sales for ARTV reached as high as 0.0% in Q3 2023 and fell as low as 3.94% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3.94% |
| Sep 30, 2024 | -0.34% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.55% |
| Dec 31, 2023 | -0.05% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | -0.03% |